Subcutaneous immunoglobulin use in inclusion body myositis: A review of 6 cases

Case Reports in Neurology

Volumn 7, Issue 3, 2015, Pages 227-232

  Cherin, Patrick ^a   Delain, Jean Christophe ^c   De Jaeger, Christophe ^b   Crave, Jean Charles ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Institut de Médecine et Physiologie de la Longévité   (France)

^c Octapharma   (France)

Author keywords

Biopsy; Corticosteroid; Immunoglobulin; Inclusion body myositis; Muscle weakness; Subcutaneous immunoglobulins

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL;

ADULT; AGED; ARTHRALGIA; ASTHENIA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE STRENGTH; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84974530784     PISSN: 1662680X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000441490     Document Type: Review

References (15)

1. Dalakas MC: Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-447.
2. Chahin N, Engel AG: Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-424.
3. Needham M, Mastaglia FL: Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008;18:6-16.
4. Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
5. Dalakas MC: Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998;51:S37-S45.
6. Dalakas MC: Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51:S2-S8.
7. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E: A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.
8. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D: High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28.
9. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B: Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326.
10. Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M: Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 2013;48:838-839.
11. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA: A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011;134:3167-3175.
12. Lindberg C, Oldfors A: Prognosis and prognostic factors in sporadic inclusion body myositis. Acta Neurol Scand 2012;125:353-358.
13. Mastaglia FL, Phillips BA, Zilko P: Treatment of inflammatory myopathies. Muscle Nerve 1997;20:651-664.
14. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, Stojkovic T, Leite MI, Allenbach Y, Herson S, et al: Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-3184.
15. Dobloug C, Walle-Hansen R, Gran JT, Molberg O: Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 2012;30:838-842.